Aura Biosciences, Inc.
AURAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. With a market capitalization of $723.0M, it sits in small-cap territory. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Market Cap
$723.0M
Beta
0.40
P/E (TTM)
—
P/E (Fwd)
-3.44
EPS (TTM)
$-1.71
EPS (Fwd)
$-2.03
ROE
-95.6%
ROA
-50.6%
Cash
$114.7M
Total Debt
$17.0M
Free CF
-$51.6M
52W Change
4.2%
Annual Financials
Cash vs Debt
Aura Biosciences, Inc. holds $114.7M in cash against $17.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$51.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -95.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Aura Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, AURA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aura Biosciences, Inc. and its sector.